Sex-related differences in non-urothelial variant histology, non-muscle invasive bladder cancer

Rocco Simone Flammia1,2, Francesco Chierigo2,3, Christoph Würnschimmel2,4, Mike Wenzel2,5, Benedikt Horlemann2, Zhen Tian2, Marco Borghesi3, Costantino Leonardo1, Derya Tilki4,6, Shahrskh F. Shariat7–10, Umberto Anceschi11, Felix K.H. Chun9, Carlo Terrone3, Fred Saad2, Michele Gallucci1, Pierre I. Karakiewicz2

1Department of Maternal-Child and Urological Sciences, Sapienza University Rome, Policlinico Umberto I Hospital, Rome, Italy
2Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, Montréal, Québec, Canada
3IRCCS Ospedale Policlinico San Martino, Genova, Italy
4Martini-Klinik Prostate Cancer Center, University Hospital Hamburg-Eppendorf, Hamburg, Germany
5Department of Urology, University Hospital Frankfurt, Frankfurt am Main, Germany
6Department of Urology, University Hospital Hamburg-Eppendorf, Hamburg, Germany
7Department of Urology, Weill Cornell Medical College, New York, New York, USA
8Department of Urology, University of Texas Southwestern, Dallas, Texas, USA
9Division of Urology, Department of Special Surgery, Jordan University Hospital, The University of Jordan, Amman, Jordan
10Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria
11Department of Surgical Sciences, Sapienza Rome University, Rome, Italy

Article history
Submitted: March 5, 2022
Accepted: July 4, 2022
Published online: July 18, 2022

Introduction
Non-urothelial variant histology (VH), non-muscle invasive bladder cancer (NMIBC) has received little attention in contemporary urologic literature. Specifically, the effect of female sex on stage at presentation, as well as on cancer-specific mortality (CSM) have not been previously examined in VH NMIBC. Our aim was to test the effect of female sex on stage at presentation and CSM in VH NMIBC.

Material and methods
Within the Surveillance, Epidemiology, and End Results (SEER) database (2004–2016), we identified patients aged ≥18 years, with histologically confirmed VH NMIBC. Logistic regression models addressed T1 stage at diagnosis after multivariable adjustments for tumor grade, age and race/ethnicity. Before Kaplan-Meier plots and Cox regression analyses, propensity score matched adjusting for histological variants, T-stage, tumor grade, age and race/ethnicity was performed.

Results
Overall, 2,205 VH NMIBC patients were identified. Of those, 28% (n = 607) were female. Females were older (77 vs 74 years, p <0.001) and more frequently harbored T1 stage (55 vs 45%, p <0.001). Female sex independently predicted T1 stage (odds ratio [OR] = 1.66, 95% Confidence Interval [CI] = 1.35–2.03, p <0.001). Female sex also exhibited higher CSM, after matching for all assessable variables, including stage (hazard ratio [HR] = 1.91, 95% CI = 1.45–2.54, p <0.001).

Conclusions
In VH NMIBC, female sex is an indicator of higher rate of T1 stage and, fully independently of stage, female sex also results in higher CSM.

Key Words: non-muscle invasive bladder cancer • adenocarcinoma • neuroendocrine carcinoma • variant histology • squamous cell carcinoma • Surveillance, Epidemiology, and End Results

INTRODUCTION
Non-urothelial variant histology (VH) accounts for 10 to 25% of bladder cancers (BCa) [1, 2]. Relative to urothelial, non-urothelial variant histology non-muscle invasive bladder cancer (VH NMIBC) has received relatively little attention in all aspects. Specifically, the association between female sex and stage at presentation of VH NMIBC has not been examined. Similarly, the association between female sex and cancer-specific mortality in VH NMIBC needs to be investigated.
sex and cancer-specific mortality (CSM) has also not been addressed. We addressed these voids within the most contemporary Surveillance, Epidemiology, and End Results (SEER) database (2004–2016). We relied on the 2016 World Health Organization (WHO) classification and addressed four different VH NMIBC groups, namely squamous cell carcinoma (SCC), adenocarcinoma (AD), neuroendocrine carcinoma (NE), and other types (Other VH) [3]. We hypothesized that female sex affects stage at presentation and CSM, in patients with VH NMIBC.

**MATERIAL AND METHODS**

**Study population**

Within the Surveillance, Epidemiology, and End Results (SEER) database (2004–2016), we identified patients treated with transurethral bladder tumor resection (TURBT), aged ≥18 years, with histologically confirmed BCa (International Classification of Disease for Oncology site code C67.0-9) of NMIBC (≤T1N0M0), according to the American Joint Committee on Cancer (AJCC), seventh edition. Mixed histology is not coded in the SEER database. Thus, definition of non-urothelial variant histology reflected the predominant histologic subtype [1]. According to the 2016 World Health Organization (WHO) classification, four major non-urothelial histologic variants BCa of all grades were included: squamous cell carcinoma (SCC) [4], adenocarcinoma (AD) [5], neuroendocrine carcinoma (NE) [6], and other types (Other VH) [3]. Patients with a diagnosis of urothelial carcinoma of urinary bladder (UCUB), as well as autopsy, death certificate-only cases and patients receiving radiotherapy and/or chemotherapy and/or surgical treatment different from TURBT, according to SEER surgery code, were excluded.

**Statistical analyses**

First, we examined the association between female sex and T stage at diagnosis. Tabulations were complemented with univariable and multivariable logistic regression models (LRM) predicting T1 stage. The main predictor consisted of female vs male sex. Second, we focused on CSM and relied on Kaplan-Meier plots and Cox regression models. The main predictor consisted of female vs male sex. To adjust for sociodemographic and clinical differences between females and males, propensity score matching (PSM) was applied. One to one PSM was applied and relied on histological variants (SCC, AD, NE and Other), T-stage (Ta, Tis, T1), tumor grade (G1–G2, G3–G4 and unknown), age at diagnosis (one-year interval) and race/ethnicity.

**Table 1. Descriptive characteristics of 2,205 patients diagnosed with non-urothelial variant histology non-muscle invasive bladder cancer (VH-NMIBC), according to sex (female vs male)**

| Variable                  | Overall (n = 2,205) | Male (n = 1,598, 72%) | Female (n = 607, 28%) | p-value |
|---------------------------|---------------------|-----------------------|-----------------------|---------|
| Age at diagnosis (years)  | Median (IQR)        | 75 (65–82)            | 74 (65–81)            | 77 (68–84) | <0.001 |
| Follow-up (months)        | Median (IQR)        | 40 (12–87)            | 44 (16–88)            | 28 (6–82) | <0.001 |
| Race/ethnicity            |                     |                       |                       |         |
| Caucasian                 | 1,832 (83.1)        | 1,334 (83.5)          | 498 (82.0)            |         |
| African–American          | 143 (6.5)           | 94 (5.9)              | 49 (8.1)              | 0.3     |
| Hispanic–Latinos          | 128 (5.8)           | 97 (6.1)              | 31 (5.1)              |         |
| Unknown/other             | 102 (4.6)           | 73 (4.6)              | 29 (4.8)              |         |
| Variant histology         |                     |                       |                       | <0.001  |
| Squamous cell carcinoma   | 949 (43.0)          | 639 (40.0)            | 310 (51.1)            |         |
| Adenocarcinoma            | 316 (14.3)          | 245 (15.3)            | 71 (11.7)             |         |
| Neuroendocrine carcinoma  | 104 (4.7)           | 83 (5.2)              | 21 (3.5)              |         |
| Other                     | 836 (37.9)          | 631 (39.5)            | 205 (33.8)            |         |
| T stage                   |                     |                       |                       | <0.001  |
| Ta                        | 594 (26.9)          | 458 (28.7)            | 136 (22.4)            |         |
| Tis                       | 588 (26.7)          | 453 (28.3)            | 135 (22.2)            |         |
| T1                        | 1,023 (46.4)        | 687 (43.0)            | 336 (55.4)            |         |
| Tumor grade               |                     |                       |                       | 0.037   |
| Low-grade                 | 662 (30.0)          | 457 (28.6)            | 205 (33.8)            |         |
| High-grade                | 700 (31.7)          | 509 (31.9)            | 191 (31.5)            |         |
| Unknown                   | 843 (38.2)          | 632 (39.5)            | 211 (34.8)            |         |

n – number of patients; IQR – interquartile range
Figure 1. Stacked bar plots depicting stage at presentation (T1 vs Tis–Ta) according to patient sex in the overall cohort and within non-urothelial variant histology non-muscle invasive bladder cancer (VH NMIBC) subgroups.

n = number of patients, VH – variant histology; p = p-value

Effect of female sex on tumor stage

Females were more frequently diagnosed with T1 stage than males (55 vs 45%, p <0.001). This difference applied to the overall VH NMIBC cohort and also specifically applied to SCC and Other (p <0.010, Figure 1), but not to AD and NE (Figure 1).

In the overall VH NMIBC cohort, female sex was an independent predictor of T1 stage, after adjustment for age, tumor grade and race (OR = 1.66, p <0.001, Table 2). Moreover, within VH NMIBC subgroups, female sex was an independent predictor of T1 stage in SCC (OR = 2.21, p <0.001) and Other (OR = 1.77, p = 0.002), but not in AD and NE (Table 2).

Effect of female sex on cancer-specific mortality

In the overall VH NMIBC cohort, PSM was applied between 607 females and 1598 males. One to one PSM (VH, T-stage, tumor grade, age and race) resulted in two equally sized groups of 607 females.
tumor grade, age and race) resulted in two equally sized groups of 310 females vs 310 males, with no residual statistically significant differences in T stage, tumor grade, age and race. In Kaplan-Meier plots (Figure 3A), five-year CSM free-survival was 71% (95% CI = 66–77%) for females vs 88% (95% CI = 84–92%) for males (log-rank test, p <0.001), which translated into a hazard ratio (HR) of 2.42 (1.64–3.56, p <0.001).

In AD patients (n = 316, 14%), PSM was applied between 71 females and 245 males. One to one PSM (T stage, tumor grade, age and race) resulted in two groups of 71 females vs 71 males, with no residual statistically significant differences in T stage, tumor grade, age and race. In Kaplan-Meier plots (Figure 3B), five-year CSM-free survival was 70% (95% CI = 59–84%) for females vs 81% (95% CI = 71–93%) for males (log-rank test, p = 0.2), which translated into a hazard ratio (HR) of 1.55 (0.73–3.30, p = 0.3).

In NE patients (n = 104, 5%), PSM was applied between 21 females and 83 males. One to one PSM (T stage, tumor grade, age and race) resulted in two groups of 19 females vs 19 males, with no residual statistically significant differences in T stage, tumor grade, age and race. No sex-related differences in CSM were recorded in this subgroup. In Kaplan-Meier plots (Figure 3C), five-year CSM-free survival was 75% (95% CI = 59–94%) for females vs 66% (95% CI = 45–97%) for males (log-rank test, p = 0.5), which translated into a hazard ratio (HR) of 0.62 (0.14–2.62, p = 0.5).

In Other VH patients (n = 936, 38%), PSM was applied between 205 females and 631 males. One to one PSM (T stage, tumor grade, age and race) resulted in two equally sized groups of 310 females vs 310 males, with no residual statistically significant differences in T stage, tumor grade, age and race. In Kaplan-Meier plots (Figure 2), five-year CSM free-survival was 75% (95% CI = 71–79%) for females vs 84% (95% CI = 81–87%) for males (log-rank test, p <0.001), which translated into a hazard ratio (HR) of 1.91 (1.45–2.54, p <0.001) for females vs males. Subsequently, all the above steps including PSM were repeated in each VH NMIBC subgroup. In SCC patients (n = 949, 43%), PSM was applied between 310 females and 639 males. One to one PSM (T stage, tumor grade, age and race) resulted in two equally sized groups of 310 females vs 310 males, with no residual statistically significant differences in T stage, tumor grade, age and race. In Kaplan-Meier plots (Figure 3A), five-year CSM free-survival was 71% (95% CI = 66–77%) for females vs 88% (95% CI = 84–92%) for males (log-rank test, p <0.001), which translated into a hazard ratio (HR) of 2.42 (1.64–3.56, p <0.001).

In AD patients (n = 316, 14%), PSM was applied between 71 females and 245 males. One to one PSM (T stage, tumor grade, age and race) resulted in two groups of 71 females vs 71 males, with no residual statistically significant differences in T stage, tumor grade, age and race. In Kaplan-Meier plots (Figure 3B), five-year CSM-free survival was 70% (95% CI = 59–84%) for females vs 81% (95% CI = 71–93%) for males (log-rank test, p = 0.2), which translated into a hazard ratio (HR) of 1.55 (0.73–3.30, p = 0.3). In NE patients (n = 104, 5%), PSM was applied between 21 females and 83 males. One to one PSM (T stage, tumor grade, age and race) resulted in two groups of 19 females vs 19 males, with no residual statistically significant differences in T stage, tumor grade, age and race. No sex-related differences in CSM were recorded in this subgroup. In Kaplan-Meier plots (Figure 3C), five-year CSM-free survival was 75% (95% CI = 59–94%) for females vs 66% (95% CI = 45–97%) for males (log-rank test, p = 0.5), which translated into a hazard ratio (HR) of 0.62 (0.14–2.62, p = 0.5). In Other VH patients (n = 936, 38%), PSM was applied between 205 females and 631 males. One to one PSM (T stage, tumor grade, age and race) re-

---

**Table 2. Univariable and multivariable logistic regression analyses predicting T1 in overall cohort of non-urothelial variant histology non-muscle invasive bladder cancer (VH-NMIBC), as well as in squamous cell carcinoma (SCC), adenocarcinoma (AD), neuroendocrine carcinoma (NE) and others types (Other VH). Multivariable adjustments were made for tumor grade, patients age and race. Patient sex (female vs male) represented the main predictor**

|                    | Univariable logistic regression | Multivariable logistic regression |
|--------------------|--------------------------------|---------------------------------|
|                    | OR (95% CI)                    | p-value | OR (95% CI) | p-value |
| Overall (n = 2205) | Female vs male                 | 1.64 (1.36–1.99) | <0.001 | 1.66 (1.35–2.03) | <0.001 |
| Squamous cell carcinoma (n = 949) | Female vs male | 2.12 (1.61–2.80) | <0.001 | 2.21 (1.63–3.00) | <0.001 |
| Adenocarcinoma (n = 316) | Female vs male | 1.03 (0.55–2.02) | 0.9 | 1.01 (0.53–2.01) | 1 |
| Neuroendocrine carcinoma (n = 104) | Female vs male | 0.24 (0.01–6.35) | 0.3 | 0.23 (0.01–6.80) | 0.3 |
| Other VH (n = 836) | Female vs male                 | 2.01 (1.45–2.77) | <0.001 | 1.77 (1.24–2.53) | 0.002 |

n – number of patients; VH – variant histology; OR – odds ratio; CI – confidence interval
these three hypotheses within the SEER database and observed important differences between females vs males.

First, we observed sex distribution differences and age distribution differences in VH NMIBC. Specifically, female sex was less frequent in the overall cohort, as well as in all VH NMIBC subgroups. Similarly, females were older in the overall VH NMIBC cohort, as well as in SCC, AD, and Other VH NMIBC subgroups but not in NE.

Second, we also observed sex-specific stage distribution differences. Specifically, females more frequently harbored T1 stage vs males. This observation applied to the overall VH NMIBC cohort, as well as to SCC and Other VH, but not to AD and NE. Independent predictor status of female sex for T1 stage was

**DISCUSSION**

We hypothesized that female sex affects stage at presentation and CSM among patients with VH NMIBC. Moreover, we tested whether stage and CSM sex-related differences also applies to VH NMIBC subgroups, namely SCC, AD, NE and Other VH. We explored
observed in multivariable logistic regression models in the overall VH NMIBC cohort, as well as in SCC and Other VH, but not in AD and NE. In consequence, female sex predisposes to T1 stage in VH NMIBC and specifically, in SCC and Other VH. Third, female sex exhibited higher CSM, after matching for stage, in the overall VH NMIBC cohort. Moreover, higher CSM in females, after matching, also applied to SCC, but not to AD, NE and Other VH. In consequence, in SCC, female sex should not only be interpreted as a risk factor for higher stage, but also for higher CSM. Lack of association between female sex and CSM in the AD, NE and Other VH, might be related to limited sample size or might reflect true absence of association. Unfortunately, our observations were too scant to distinguish between these two explanations.

Fourth, it is important to emphasize a two-step process, whereby female sex independently predisposes to both more advanced stage and higher CSM, even after adjustment for stage and other variables in CSM models. This two-step adverse relationship between female sex and stage, as well as female sex and CSM, was previously described by Rosiello et al. in UCUB treated with radical cystectomy [8]. Similarly, other studies reported stage disadvantage and higher CSM in females vs males [9–12]. However, to the best of our knowledge, the relation between female sex and T1 stage, as well as female sex and T1 stage, was never specifically examined in a population-based cohort of VH NMIBC treated with TURBT. Consequently, our findings cannot be directly compared to previous reports.

The clinical implications of our findings are two-fold. First, it may be possible that female sex does not represent a biological determinant of more advanced stage in VH NMIBC, as well as in UCUB treated with cystectomy. Under such scenario, as reported by Rosiello et al., stage disadvantage in females may reflect a female-specific delay in BCa diagnosis. Indeed, sex-related differences in referral patterns were reported by Mansson et al. [13], who found that a higher proportion of females with BCa were referred to a department other than urology (26.9 vs 3.7%) for initial hematuria work-up compared to males. Moreover, Cohn et al. reported significantly longer delays from initial hematuria diagnosis to urological assessment in females vs males (85.4 vs 73.6 days, p <0.001) [14]. These findings are not surprising, since in females, most general practitioners associate microscopic or even gross hematuria with urinary tract infections [15]. In consequence, efforts should be made to implement better referral patterns and to avoid, or even to eliminate diagnostic delays [16]. Last but not least, detailed longitudinal studies should examine whether delays in diagnosis represent a valid explanation for the stage disadvantage observed in females or whether female sex truly represents a biological determinant of more advanced stage. Unfortunately, the nature of our database does not allow us to address this question.

The second clinical implication of our work pertains to increased risk of CSM observed in females, after adjustment for stage. Here, the relation between female sex and higher CSM purely and evidently no longer can be explained by diagnostic delays, since stage adjustment was made. In consequence, it may be postulated with reasonable certainty that female sex represents a biological determinant of higher CSM, in VH NMIBC, to a similar extent that was reported by Rosiello et al. in UCUB treated with radical cystectomy. Unfortunately, other important variables, such as number of recurrences [17], TURBT completeness [18], use of intravesical therapy [19], type of intravesical therapy [20], presence of associated carcinoma in situ (CIS) [21], molecular or mutational characteristics [22], smoking [23, 24] and environmental exposure [25] or estrogen effect [26] are routinely not documented in institutional or population databases, although they may also have contributed to these sex-related differences [27]. For example, it is possible that female patients were even more prone to under-staging, since the higher risk of bladder perforation during TURB would prevent surgeons from performing a more aggressive local surgical treatment [28]. Previous studies, looking at non-urothelial VH NMIBC, have reported local under-staging rates of 27% to 57% in clinical stage T1 [29, 30] and rates of occult metastatic disease as high as 27% to 44% [31]. Hypothetically, a higher percentage of patients staged as T1 among women compared to men, might directly correlate to an increased proportion of under-staging in the former group.

To the best of our knowledge, we are the first to report the association between female sex and T1 stage, as well as female sex and higher CSM in VH NMIBC. Nonetheless, we are expanding upon previous findings of Rosiello et al. Despite the novelty of our findings, our observations are limited in several regards. First, our findings are based on limited sample size. However, the current cohort represents the largest group of VH NMIBC ever reported. Nonetheless, subgroups of our cohort were still too small to allow valid analyses. Second, our analysis is retrospective, with all inherent biases such as absence of centralized analysis of TURB specimen. However, no prospective studies investigating VH NMIBC have been published so far. Third, TURBT related information is unknown (surgeons’ experience, TURBT completeness, etc.). Last but
not least, recurrence and progression rates are unknown. In consequence, progression rates to muscle invasive, as well as to radical cystectomy cannot be assessed. Nonetheless, our survival analysis allows assessment of CSM, which represents the ultimate and most valid endpoint. These, as well as all other limitations related to the retrospective, population-based nature of the SEER database, apply to this, as to other similar analyses that were based on the SEER database or on other similar large-scale data repositories, such as the National Cancer Data Base, National Inpatient Sample, or National Surgical Quality Improvement Program.

CONCLUSIONS

In VH NMIBC, female sex is an indicator of higher rate of T1 stage and, fully independently of stage, female sex also results in higher CSM.

References

1. Deuker M, Martin T, Stolzenbach F, et al. Bladder Cancer: A Comparison Between Non-urothelial Variant Histology and Urothelial Carcinoma Across All Stages and Treatment Modalities. Clin Genitourin Cancer. 2021; 19: 60-68.e1.

2. Wasco MJ, Daignault S, Zhang Y, et al. Urothelial Carcinoma with Divergent Histologic Differentiation (Mixed Histologic Features) Predicts the Presence of Locally Advanced Bladder Cancer When Detected at Transurethral Resection. Urology. 2007; 70: 69-74.

3. Humphrey PA, Moch H, Cubilla AL, Ulbright TM, Reuter VE. The 2016 WHO Classification of Tumours of the Urinary System and Male Genital Organs - Part B: Prostate and Bladder Tumours. Eur Urol. 2016; 70: 106-119.

4. Abdel-Rahman O. Squamous Cell Carcinoma of the Bladder: A SEER Database Analysis. Clin Genitourin Cancer. 2017; 15: e463-e468.

5. Natale C, Leinwand GZ, Chiang J, et al. Acquisition of data: Benedikt Horlemann, Mikel Wenzel. Analysis and interpretation of data: Rocco Simone Flammia, Christoph Würnschimmel. Drafting the manuscript: Rocco Simone Flammia, Pierre I. Karakiewicz. Critical revision of the manuscript: Shahrokh F. Shariat, Costantino Leonardo, Marco Borghesi, Umberto Aneschi. Statistical analysis: Rocco Simone Flammia, Francesco Chierigo, Zhe Tian. Supervision: Fred Saad, Michele Gallucci, Felix K.H. Chun, Derya Tilki, Carlo Terrone.

CONFLICTS OF INTEREST

The authors declare no conflicts of interest.

AUTHORSHIP CONTRIBUTION STATEMENT*

Conceptualization: Rocco Simone Flammia, Pierre I. Karakiewicz. Acquisition of data: Benedikt Horlemann, Mikel Wenzel. Analysis and interpretation of data: Rocco Simone Flammia, Christoph Würnschimmel. Drafting the manuscript: Rocco Simone Flammia, Pierre I. Karakiewicz. Critical revision of the manuscript: Shahrokh F. Shariat, Costantino Leonardo, Marco Borghesi, Umberto Aneschi. Statistical analysis: Rocco Simone Flammia, Francesco Chierigo, Zhe Tian. Supervision: Fred Saad, Michele Gallucci, Felix K.H. Chun, Derya Tilki, Carlo Terrone.

*Adapted from Reproduced from Brand et al. (2015), Learned Publishing 28(2), with permission of the authors.
central European Journal of Urology

Mass index as risk factors for bladder perforation during primary transurethral resection of bladder tumors. J Urol. 2012; 187: 1566-1570.

19. Boorjian SA, Zhu F, Herr HW. The effect of gender on response to bacillus Calmette-Guérin therapy for patients with non-muscle-invasive urothelial carcinoma of the bladder. BJU Int. 2010; 106: 357-361.

20. D’Andrea D, Soria F, Abufaraj M, et al. Comparative Effectiveness of Intravesical BCG-Tice and BCG-Moreau in Patients With Non-muscle-invasive Bladder Cancer. Clin Genitourin Cancer. 2020; 18: 20-25.e2.

21. Alanee S, Bauman J, Dynda D, Frye T, Konety B, Schwartz B. Conservative management and female gender are associated with increased cancer-specific death in patients with isolated primary urothelial carcinoma in situ. Eur J Cancer Care (Engl). 2015; 24: 444-449.

22. Dobruch J, Daneshmand S, Fisch M, et al. Gender and Bladder Cancer: A Collaborative Review of Etiology, Biology, and Outcomes. Eur Urol. 2016; 69: 300-310.

23. Freedman ND, Silverman DT, Hollenbeck AR, Schatzkin A, Abnet CC. Association between smoking and risk of bladder cancer among men and women. JAMA. 2011; 306: 737-745.

24. Crivelli JJ, Xylinas E, Kluth LA, Rieken M, Rink M, Shariat SF. Effect of smoking on outcomes of urothelial carcinoma: A systematic review of the literature. Eur Urol. 2014; 65: 742-754.

25. Volanis D, Kadiyska T, Galanis A, Delakas D, Logotheti S, Zoumpourlis V. Environmental factors and genetic susceptibility promote urinary bladder cancer. Toxicol Lett. 2010; 193: 131-137.

26. Mir C, Shariat SF, Van Der Kwast TH, et al. Loss of androgen receptor expression is not associated with pathological stage, grade, gender or outcome in bladder cancer: A large multi-institutional study. BJU Int. 2011; 108: 24-30.

27. Radkiewicz C, Edgren G, Johansson ALV, et al. Sex Differences in Urothelial Bladder Cancer Survival. Clin Genitourin Cancer. 2020; 18: 26-34.

28. Hollenbeck BK, Dunn RL, Ye Z, et al. Delays in diagnosis and bladder cancer mortality. Cancer. 2010; 116: 5235-5242.

29. Hansel DE, Amin MB, Comperat E, et al. A contemporary update on pathology standards for bladder cancer: Transurethral resection and radical cystectomy specimens. Eur Urol. 2013; 63: 321-332.

30. Weizer AZ, Wasco MJ, Wang R, Daignault S, Lee CT, Shah RB. Multiple Adverse Histological Features Increase the Odds of Under Staging T1 Bladder Cancer. J Urol. 2009; 182: 59-65.

31. Abdollah F, Sun M, Jeldres C, et al. Survival after radical cystectomy of non-bilharzial squamous cell carcinoma vs urothelial carcinoma: A competing-risks analysis. BJU Int. 2012; 109: 564-569.